MAY IS BLADDER CANCER AWARENESS MONTH A TIME TO SHINE A LIGHT ON THIS OFTEN OVERLOOKED DISEASE THAT AFFECTS THOUSANDS OF PEOPLE EACH YEAR. JOINING ME NOW IS DOCTOR MURAD ABELARDO, A UROLOGIST WITH ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

Imfinzi is approved for muscle-invasive bladder cancer and is under investigation in various stages and combinations for bladder cancer treatment. Imfinzi plus BCG induction and maintenance therapy ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

Washington, D.C. (WNCT) — Congressman Greg Murphy, M.D., is recognizing May as Bladder Cancer Awareness Month. “While most bladder cancers are caught early, it can be a terrible disease that ...

You usually have a number of tests to find out if the symptoms you have could be due to bladder cancer. If you have bladder cancer, you then need more tests to find out how far it has grown. Your GP ...

Imfinzi is approved in the US and other countries for patients with muscle-invasive bladder cancer (MIBC) based on results from the NIAGARA Phase III trial and continues to be investigated across ...

Your GP should arrange for you to see a specialist if you have symptoms that could be due to bladder cancer. Depending on your symptoms and other factors, this might be an urgent suspected cancer ...

(A) Transmission electron microscopy (scale bar = 100 nm). (B) Western blot. (C) Nanoparticle tracking analysis. (D) A total of 35 lncRNAs were significantly up-regulated in the intersection ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...